STOCK TITAN
  1. Home
  2. News
  3. IGMS

Igm Biosciences, Inc. - IGMS STOCK NEWS

Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.

IGM Biosciences, Inc. (IGMS) is a clinical-stage biotechnology company pioneering IgM antibody therapeutics for cancer, autoimmune disorders, and inflammatory diseases. This page serves as the definitive source for official news, press releases, and financial updates directly from the company and verified partners.

Investors and stakeholders will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations with global pharmaceutical leaders. The curated content includes earnings reports, research breakthroughs, and pipeline advancements related to the company’s proprietary IgM platform, which enables multispecific antibody engineering.

Bookmark this page to track IGM Biosciences’ progress in developing novel therapies that leverage the unique binding capabilities of IgM antibodies. Visit regularly for unfiltered access to critical updates that may impact long-term investment strategies and sector analysis.

News

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Rhea-AI Summary
IGM Biosciences, Inc. (IGMS) CEO to participate in fireside chat at Stifel 2024 Virtual Targeted Oncology Forum. Webcast details available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.41%
Tags
conferences
-
News

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
IGM Biosciences, Inc. (IGMS) announces financial results for Q4 and full year 2023, highlighting progress in clinical development of lead product candidates. The company provides updates on aplitabart and imvotamab trials, with promising enrollment and data expectations. Financially, the company reports cash and investments of $337.7 million, collaboration revenues of $2.1 million, R&D expenses of $215.5 million, and a net loss of $246.4 million for 2023. IGM anticipates full year 2024 operating expenses of $210-$220 million and collaboration revenue of $3 million, aiming to maintain a cash balance of $180 million to support operations until Q2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
earnings
-
News

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) announced that CEO Fred Schwarzer will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will be webcast live and available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.17%
Tags
conferences
News

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. CEO Fred Schwarzer to discuss the company's progress in developing engineered IgM antibodies. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Medivir to present at the Carlsquare Equity Research Investor Day

Rhea-AI Summary
Medivir AB (MVIR) to present at Carlsquare Equity Research Investor Day, focusing on the latest developments and future plans, including a rights issue and the development program for fostrox with the aim of starting a pivotal phase 2b study in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
-
News

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Rhea-AI Summary
IGM Biosciences, a clinical-stage biotechnology company (Nasdaq: IGMS), will focus on treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and autoimmune diseases using IgM T cell engager antibodies. The company plans to file an Investigational New Drug (IND) application for IGM-2644 (CD38 x CD3) to treat autoimmune diseases. All clinical development in hematologic oncology indications has been halted, and the company expects its cash runway to extend into the second quarter of 2026. A reduction in the workforce of approximately 22 percent is also expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
News

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Rhea-AI Summary
Medivir AB (publ) (MVIR) held an extraordinary general meeting in Stockholm, adopting a resolution to approve a rights issue for new common shares with preferential rights for existing shareholders. The rights issue includes an issue of not more than 55,841,401 new common shares, increasing the Company's share capital by not more than SEK 27,920,700.50. The new shares are issued at a subscription price of SEK 2.65 per share, with a record date for participation in the new issue set for 5 December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.79%
Tags
none
-
News

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Rhea-AI Summary
Medivir AB (MVIR) has developed an updated commercial formulation of fostrox, a potential treatment for hepatocellular carcinoma (HCC), a life-threatening form of liver cancer. The formulation was developed in collaboration with Quotient Sciences, the company's partner for formulation development and drug manufacture. Fostrox is currently being evaluated in a phase 1b/2a study in combination with Lenvima®, showing promising interim data for HCC patients who have progressed on current first-line standard of care. The company plans to initiate a phase 2b study with accelerated approval intent based on the positive results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none
-
News

Medivir to present at the Redeye Life Science Day

Rhea-AI Summary
Medivir AB (MVIR) to Participate at Redeye Life Science Day; CEO to Discuss Latest Developments and Future Plans
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
conferences
News

Medivir to present at the Erik Penser Bank Company Event

Rhea-AI Summary
Medivir AB (MVIR) to Present at Erik Penser Bank Company Event on November 23
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
conferences
Stock IGMS logo
Igm Biosciences, Inc.

Nasdaq:IGMS

IGMS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

IGMS Stock Data

72.93M
31.06M
38.81%
59.41%
1.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW